Exhibit X

Description of Significant Activities

Ractopamine hydrochloride
INAD / NADA
Correspondence Chronology

Date // Code	From	RE:	Technical Section
4/23/84	**Elanco**	**Request for establishing INAD file**	**Efficacy**
5/3/84	Elanco	Protocol for residue study	Residue
5/9/84 // INAD 4231	**CVM**	**Acknowledge receipt of 5/7/84 request for INAD & assign INAD number 4231**	**Efficacy**
6/7/84 // INAD 4231	Elanco	Protocol for acute toxicology study	HHSafety
7/2/84 // INAD 4231	CVM	Protocol for acute toxicology study	HHSafety
7/16/84 // INAD 4231	CVM	Protocol for residue study	Residue
7/19/84 // INAD 4231	Elanco	Request for meeting	HHSafety
8/13/84 // INAD 4231	Elanco	Protocol: swine reproductive safety study	TASS
8/13/84 // INAD 4231	Elanco	Protocol: residue depletion study	Residue
8/27/84 // INAD 4231	Elanco	Request for meeting on 9/13/84	HHSafety
9/20/84 // INAD 4231	CVM	8/13/84 Protocol	TASS
11/23/84 // INAD 4231	CVM	8/13/84 Protocol	Residue
12/21/84 // INAD 4231	Elanco	Reports: threshold assessment evaluation:	HHSafety
1/17/85 // INAD 4231	**Elanco**	**Request for slaughter authorization**	**HHSafety**
1/30/85 // INAD 4231	Elanco	Protocol: clinical efficacy	Efficacy
2/21/85 // INAD 4231	Elanco	Additional tox info	HHSafety
3/14/85 // INAD 4231	Elanco	Protocols: TAS and tolerance studies	TASS
4/4/85 // INAD 4231	Elanco	Tox study report	HHSafety
4/11/85 // INAD 4231	Elanco	Protocol: tox study	HHSafety
4/15/85 // INAD 4231	CVM	Slaughter authorization	HHSafety; Residue
5/16/85 // INAD 4231	Elanco	Protocols: stability studies	CM&C
5/29/85 // INAD 4231	CVM	Response: Protocol	Efficacy
6/7/85 // INAD 4231	CVM	Response: Protocols for stability studies	CM&C
6/13/85 // INAD 4231	Elanco	Protocol for tox study:	HHSafety
6/13/85 // INAD 4231	Elanco	Reports: residue studies	Residue
6/25/85 // INAD 4231	CVM	Protocol for TAS and tolerance study	TASS
7/10/85 // INAD 4231	CVM	4/11/85 tox Protocol	HHSafety
7/12/85 // INAD 4231	CVM	tox studies for threshold assessment	HHSafety
8/23/85 // INAD 4231	**Elanco**	**Submission: first (NCIE)**	**Efficacy**
8/28/85 // INAD 4231	CVM	Protocol for tox study	HHSafety
10/17/85 // INAD 4231	Elanco	Protocol has been modified	Efficacy
12/19/85 // INAD 4231	Elanco	Protocol: Efficacy study	Efficacy
12/19/85 // INAD 4231	Elanco	Environmental testing plan	EA
2/13/86 // INAD 4231	Elanco	Tox Study outline	HHSafety
2/25/86 // INAD 4231	CVM	Protocol is OK	Efficacy
3/18/86 // INAD 4231	CVM	Ractopamine is non-gentoxic	HHSafety
3/19/86 // INAD 4231	CVM	12/19/85 Protocol	Efficacy
3/25/86 // INAD 4231	CVM	2/13/86 Study outline	HHSafety
4/2/86 // INAD 4231	CVM	12/19/85 Environmental testing	EA
4/10/86 // INAD 4231	Elanco	Published paper	HHSafety
6/12/86 // INAD 4231	Elanco	Protocol: radiolabeled tissue residue study	Residue
8/14/86 // INAD 4231	Elanco	Statistical evaluation of clinical data	Efficacy

8/27/86 // INAD 4231	CVM	Radiolabeled tissue residue study protocol	Residue
8/28/86 // INAD 4231	Elanco	Environmental fate package	EA
10/29/86 // INAD 4231	Elanco	Radiolabeled tissue residue study protocol	Residue
11/6/86 // INAD 4231	CVM	Statistical evaluation of clinical data	Efficacy
11/20/86 // INAD 4231	CVM	8/28/86 Environmental fate	EA
12/19/86 // INAD 4231	Elanco	Additional environmental study reports	EA
1/7/87 // INAD 4231	Elanco	Balance-Excretion Study	Residue
1/22/87 // INAD 4231	Elanco	Protocol: clinical efficacy	Efficacy
1/28/87 // INAD 4231	CVM	Residue study protocol	Residue
1/29/87 // INAD 4231	Elanco	Comparative metabolism	Residue
2/19/87 // INAD 4231	CVM	Balance-Excretion Study	Residue
3/23/87 // INAD 4231	CVM	Comparative metabolism	Residue
3/23/87 // INAD 4231	CVM	Clinical efficacy protocol	Efficacy
3/23/87 // INAD 4231	CVM	Environmental study reports	EA
3/31/87 // INAD 4231	Elanco	Lab animal bioavailability studies	HHSafety
4/22/87 // INAD 4231	Elanco	Residue study	Residue
4/30/87 // INAD 4231	Elanco	Clinical protocol	Efficacy
5/14/87 // INAD 4231	Elanco	Tissue Residue Study	Residue
5/15/87 // INAD 4231	CVM	Request for slaughter authorization	Efficacy
5/28/87 // INAD 4231	Elanco	Bioavailability study report	Efficacy
6/4/87 // INAD 4231	Elanco	Reports of corroborative efficacy studies:	Efficacy
7/15/87 // INAD 4231	CVM	Bioavailability studies	HHSafety
7/15/87 // INAD 4231	CVM	Residue studies	Residue
8/27/87 // Original NADA	**Elanco**	**Original NADA,**	**ALL**
9/1/87 // NADA 140-863	**CVM**	**Acknowledge receipt of 8/27/87 original NADA, assigned number 140-863**	**ALL**
9/14/87 // INAD 4231	CVM	Bioavailability study	Efficacy
10/1/87 // NADA 140-863	Elanco	VMF assigned for bulk drug mnfg.	CM&C
10/21/87 // INAD 4231	CVM	Slaughter Authorization	Efficacy
12/1/87//NADA 140-863	Elanco	Reproductive safety in swine protocol	TASS
2/5/88 // INAD 4231	Elanco	Request for add'l slaughter authorization	Residue
3/18/88 // NADA 140-863	**CVM**	**Response: 8/27/87 original application -**	**ALL**
3/18/88 // INAD 4231	CVM	Repro safety Protocol	TASS
4/22/88	CVM	Slaughter Authorization	Efficacy
6/2/88 // NADA 140-863	Elanco	Revised label	Label
6/2/88 // NADA 140-863	Elanco	Summary report of three efficacy trials	Efficacy
8/11/88 // NADA 140-863	Elanco	Target Animal Safety section	TASS
8/18/88 // NADA 140-863	Elanco	M&C and Labeling	Label
8/30/88 // NADA 140-863	Elanco	Revised labeling	Label
9/15/88 // NADA 140-863	Elanco	EA studies	EA
10/27/88 // NADA 140-863	Elanco	Stability study	CM&C
10/27/88 // NADA 140-863	Elanco	EA studies	EA
10/28/88 // NADA 140-863	CVM	Worker safety study	EA
10/28/88 // NADA 140-863	CVM	protocol	EA
11/22/88 // NADA 140-863	Elanco	TASS data	TASS
11/28/88 // NADA 140-863	Elanco	Revised FOI summary	FOI
11/30/88 // NADA 140-863	Elanco	Manufacturing	CM&C
12/1/88 // NADA 140-863	Elanco	Feed Stability Protocols	CM&C
12/1/88 // NADA 140-863	Elanco	Bag specifications	CM&C
12/1/88 // NADA 140-863	Elanco	Statistical summaries of clinical data	Efficacy
12/15/88 // NADA 140-863	Elanco	Statistical summaries of clinical data	Efficacy
12/15/88 // NADA 140-863	Elanco	Patent info	Patent
12/19/88 // NADA 140-863	CVM	Clinical data	Efficacy
1/2/89 // NADA 140-863	Elanco	EA study	EA
1/9/89 // INAD 4231	CVM	Slaughter Authorization	Efficacy
1/11/89	CVM	Stability protocols	CM&C

1/24/89 // NADA 14-863;	Elanco	Manufacturing	CM&C
2/2/89 // NADA 140-863	Elanco	Updated labeling	Label
2/9/89 // NADA 140-863	Elanco	Tox study	EA
2/16/89 // NADA 140-863	Elanco	Tox study	TASS
2/28/89 // NADA 140-863	CVM	M&C and labeling	Label
3/2/89 // NADA 140-863	Elanco	EA information	EA
3/2/89 // NADA 140-863	Elanco	EA information	EA
3/2/89 // NADA 140-863	Elanco	Revised complete EA	EA
4/3/89 // NADA 140-863	CVM	Manufacturing	CM&C
4/3/89 // NADA 140-863	CVM	Partial response to 8/11/88 submission	TASS
4/3/89 // NADA 140-863	CVM	Efficacy evaluation	Efficacy
4/3/89 // NADA 140-863	**CVM**	**"... ractopamine does not have to meet section 558.15 criteria."**	**Microbio Safety**
4/3/89 // NADA 140-863	CVM	FOI evaluation	FOI
4/4/89 // NADA 140-863	CVM	Approving 1/24/89 M&C submission	CM&C
4/6/89 // NADA 140-863	CVM	Approving 11/30/88 M&C submission	CM&C
4/14/89 // NADA 140-863	CVM	Response	various
5/25/89 // NADA 140-863	Elanco	Acknowledge 4/14/89 letter	Residue
6/8/89 // NADA 140-863	Elanco	Partial response to 4/3/89 letter	TASS; Effic
7/17/89 // NADA 140-863	CVM	Response: 2/16/89 submission	TASS
8/9/89 // NADA 140-863	Elanco	Completion of response to 4/3/89 letter	TASS; Effic
8/9/89 // NADA 140-863	Elanco	Response to 7/17/89 letter	TASS
9/14/89 // NADA 140-863	Elanco	Swine feed assay method	Feed Method
10/12/89 // NADA 140-863	Elanco	INAD trial report	Efficacy
10/31/89 // NADA 140-863	CVM	Response to 2/2/89 submission	various
12/13/89 // NADA 140-863	Elanco	INAD trial report	Efficacy
1/11/90 // NADA 140-863	Elanco	Efficacy discussion	Efficacy
2/28/90 // NADA 140-863	CVM	Response: 8/9/89 submission	TASS
3/1/90 // NADA 140-863	Elanco	Response: 10/31/89 letter	various
3/8/90 // NADA 140-863	CVM	Method is ready for method trial	Feed Method
3/12/90 // NADA 140-863	CVM	Efficacy discussion	Label; Effic
5/9/90 // NADA 140-863	CVM	Tox studies	HHSafety
5/24/90 // NADA 140-863	Elanco	Tox summary	HHSafety
6/18/90 // NADA 140-863	Elanco	TASS data	TASS
7/19/90 // NADA 140-863	Elanco	Two residue protocols	Residue
8/20/90 // NADA 140-863	CVM	Residue protocols	Residue
9/5/90 // INAD 4231	CVM	Slaughter Authorization	Residue
9/13/90 // NADA 140-863	Elanco	Residue protocol	Residue
10/18/90 // NADA 140-863	Elanco	Protocol: efficacy trials	Efficacy
11/8/90 // NADA 140-863	CVM	Residue protocol	Residue
1/7/91 // NADA 140-863	Elanco	Residue protocol	Residue
1/17/91 // NADA 140-863	CVM	Laboratory trial of the feed method	Feed Method
1/22/91 // NADA 140-863	CVM	Tox studies	HHSafety
2/13/91 // NADA 140-863	Elanco	Data from batches of medicated feed	Feed Method
3/5/91 // NADA 140-863	Elanco	Additional patent information	Patent
3/12/91 // NADA 140-863	CVM	Efficacy protocol	Efficacy
4/8/91 // NADA 140-863	Elanco	Feed samples	Feed Method
4/12/91 // NADA 140-863	Elanco	Summary of residue data	Residue
5/10/91 // INAD 4231	Elanco	Efficacy protocols, proposed label	Label; Effic
5/30/91 // INAD 4231	Elanco	Revised efficacy protocols	Efficacy
6/28/91 // NADA 140-863	Elanco	Tissue residue studies	Residue
7/1/91 // INAD 004-231	CVM	Efficacy protocol	Efficacy
7/11/91 // NADA 140-863	Elanco	Tissue Residue Studies	Residue
7/22/91 // INAD 004-231	CVM	Revised efficacy protocols	Efficacy
7/29/91 // NADA 140-863	CVM	Residue section status	Residue
7/30/91 // INAD 4231	Elanco	Efficacy protocol	Efficacy

7/30/91 // NADA 140-863	CVM	Swine feed assay method	Feed Method
9/10/91 // INAD 4231	Elanco	Efficacy study protocol	Efficacy
9/10/91 // NADA 140-863	Elanco	Tissue residue studies	Residue
9/11/91 // INAD 4231	Elanco	Revised efficacy study protocol	Efficacy
9/16/91 // NADA 140-863	CVM	Non-pivotal efficacy studies	Efficacy
9/19/91 // NADA 140-863	CVM	Residue Studies	Residue
9/25/91 // NADA 140-863	Elanco	Residue data	Residue
10/7/91 // NADA 140-863	CVM	Tissue Residue	Residue
11/4/91 // INAD 004-231	CVM	Efficacy study protocol	Efficacy
11/4/91 // INAD 004-231	CVM	Efficacy study protocol	Efficacy
11/14/91 // NADA 140-863	Elanco	Tox data	HHSafety
11/15/91 // NADA 140-863	Elanco	Tox data	HHSafety
2/21/92 // NADA 140-863	CVM	Tox data	HHSafety
3/12/92 // INAD 004-231	CVM	Efficacy studies	Efficacy
3/17/92 // INAD 4231	Elanco	Protocol: tox study	HHSafety
4/14/92 // NADA 140-863	Elanco	Response: tox data	HHSafety
4/15/92 // INAD 4231	Elanco	Request for add'l slaughter authorization	Residue
7/1/92 // INAD 004-231	CVM	Protocol: tox study	HHSafety
7/24/92 // NADA 140-863	Elanco	Tox data	HHSafety
8/4/92 // INAD 004-231	CVM	Slaughter authorization	Efficacy
12/22/92 // NADA 140-863	CVM	Response: several submissions	various
1/11/93 // NADA 140-863	Elanco	Two tissue residue analytical methods	Tissue Method
3/3/93 // INAD 4231	Elanco	Protocol: Toxicity Study	HHSafety
4/27/93 // INAD 004-231	CVM	Protocol: Toxicity Study	HHSafety
5/21/93 // NADA 140-863	CVM	Response to several sections	various
7/6/93 // INAD 4231	Elanco	Revised protocol for tox study	HHSafety
7/7/93 // NADA 140-863	Elanco	Response: Feed Method data	Feed Method
8/12/93 // NADA 140-863	Elanco	Status request	TASS
9/16/93 // NADA 140-863	CVM	Sponsor Monitored Method Trial	Feed Method
9/30/93 // INAD 4231	Elanco	Updated and complete EA	EA
10/7/93 // INAD 004-231	CVM	7/6/93 protocol	HHSafety
10/7/93 // INAD 4231	Elanco	Tox study reports	HHSafety
10/21/93 // NADA 140-863	Elanco	Manufacture of bulk drug	CM&C
10/22/93 // INAD 4231	Elanco	Data	HHSafety
10/22/93 // NADA 140-863	Elanco	Manufacture of Type A Medicated Article	CM&C
11/3/93 // INAD 4231	Elanco	Updated efficacy section	Efficacy
11/4/93 // INAD 4231	Elanco	Patent information, labeling, and FOI summary	Label, FOI,Pat
2/1/94 // INAD (T) 004-231	CVM	**Target animal safety section is complete**	TASS
3/4/94 // NADA 140-863	Elanco	Feed method and validation	Feed Method
3/8/94 // NADA 140-863	Elanco	Data	Tissue Method
3/14/94 // INAD (H) 004-231	CVM	Tox data	HHSafety
3/16/94 // NADA 140-863	CVM	Manufacturing & EA	CM&C; EA
4/14/94 // NADA 140-863	Elanco	Amendment to feed method	Feed Method
4/20/94 // NADA 140-863	CVM	Feed Method protocol	Feed Method
4/22/94 // NADA 140-863	Elanco	Amendment to feed method	Feed Method
4/29/94 // N-140-863	CVM	Feed method	Feed Method
5/13/94 // INAD 4231	Elanco	Tox data	HHSafety
5/16/94 // NADA 140-863	CVM	Desk review has begun	Tissue Method
5/19/94 // INAD 4231	Elanco	Amendment to the patent information	Patent
8/4/94 // NADA 140-863	Elanco	Revised protocol	Feed Method
8/10/94 // N-140863	CVM	Method Trial	Tissue Method
8/18/94 // INAD (Z) 004-231	CVM	EA	EA
8/25/94 // N-140863	CVM	Revised Protocol	Feed Method
9/30/94 // INAD (E) 004-231	CVM	Effectiveness data are acceptable, dose rage of 5-20 ppm is accepted for F/G and Carcass claims with 5-day w/d	Label CM&C; Efficacy; FOI

10/05/94 // INAD (H) 4-231	CVM	Tox data, NOEL	HHSafety
11/7/94 // NADA 140-863	Elanco	Response: 9/21/94 letter	CM&C
11/14/94 // NADA 140-863	Elanco	Sponsor Monitored Method Trial	Feed Method
11/15/94 // NADA 140-863	Elanco	Regulatory method trials	Tissue Method
1/6/95 // NADA 140-863	Elanco	Update of patent information	Patent
1/18/95 // INAD 4231	Elanco	Summary report of tox study	HHSafety
2/3/95 // N-140863	CVM	Method trial	Tissue Method
2/15/95 // V005182-C-004	CVM	Manufacturing	CM&C
2/21/95 // INAD 4231	Elanco	Final report tox study	HHSafety
2/28/95 // N-140863	CVM	Sponsor monitored feed method trial	Feed Method
3/7/95 // N-140863-G-0064	CVM	Response: 11/7/94 submission	CM&C
3/9/95 // NADA 140-863	Elanco	Pelleted swine feed stability study	Label, CM&C
3/10/95 // NADA 140-863	Elanco	Revised procedures for tissue residues	Tissue Method
3/22/95 // NADA 140-863	Elanco	Revised feed method trial protocol	Feed Method
4/25/95 // INAD 4231	Elanco	VMF	CM&C
4/27/95 // NADA 140-863	Elanco	Request PAI	CM&C
5/2/95 // INAD 4231	Elanco	VMF	HHSafety
5/4/95 // INAD 4231	Elanco	Updated and complete EA	EA
5/5/95 // INAD 4231	Elanco	Pivotal clinical trial data analysis	Efficacy
5/11/95 // INAD 4231	Elanco	TASS data	TASS
5/16/95 // N-140863	CVM	Laboratory phase of the method trial	Feed Method
6/1/95 // INAD 4231	Elanco	TASS data	TASS
6/5/95 // INAD 4231	Elanco	Residue data	Residue
6/8/95 // NADA 140-863	Elanco	Update of patent information	Patent *
7/17/95 // I-004231	CVM	Pelleting stability	Label, CM&C
7/17/95 // I-004231	CVM	Method for ractopamine in feed	Feed Method
8/2/95 // INAD 4231	Elanco	Method trial & revised analytical method	Feed Method
8/22/95 // INAD 4231	CVM	**0-day w/d is acceptable**	Residue
8/23/95 // I-004231	CVM	Sponsor Monitored Method Trial	Tissue Method
9/22/95 // INAD 4231	CVM	**Safe tissue concentrations of 0.25 ppm (muscle), 0.75 ppm (liver), 1.5 ppm (kidney or fat)**	HHSafety; Residue
10/16/95 // NADA 140-863	Elanco	Update of patent information	Patent
10/23/95 // INAD 4231	Elanco	Revised methods	Tissue Method
10/24/95 // INAD 4231	Elanco	Sponsor Monitored Method Trial Protocol	Tissue Method
10/25/95 // I-004231	CVM	**Analytical Method for Feed approved, regulatory limits in feed set at 80 to 110% of label claim**	Feed Method
10/25/95 // Z 004231	CVM	EA	EA
11/15/95 // I-0042310	CVM	Sponsor Monitored Method Trial Protocol	Tissue Method
11/15/95 // I-004231	CVM	Method trial	Tissue Method
11/21/95 // E 004-231	CVM	**effectiveness data (performance, carcass) are acceptable, dose rage of 5-20 ppm is accepted for F/G and Carcass claims with 0-day w/d - effectiveness component is complete**	Label; Efficacy
11/27/95 // INAD 4231	Elanco	Updated environmental assessment	EA
12/6/95 // T 004-231	CVM	**Target animal safety section is complete**	TASS
12/7/95 // INAD 4231	Elanco	Sponsor Monitored Method Trial Protocol	Tissue Method
1/19/96 // I-004231	CVM	Sponsor Monitored Method Trial Protocol	Tissue Method
1/25/96 // INAD 4231	Elanco	Confirmatory Method Trial Protocol	Tissue Method
2/19/96 // INAD 4231	Elanco	Determinative Method Trial Protocol	Tissue Method
2/20/96 // I-004231	CVM	Confirmatory Method Trial Protocol	Tissue Method
3/5/96 // I-004231	CVM	Determinative Tissue Residue Method	Tissue Method
3/8/96 // V-005182	CVM	bulk drug manufacturing	CM&C
4/17/96 // V-005477	CVM	**Limits for Type A Med Article are 85 – 105% of labeled claim or NLT 7.7 g/lb (17 g/kg) and NMT 10.5 g/lb (21 g/kg).**	CM&C

6/3/96 // I-004231	CVM	**EA technical section complete**	EA
7/12/96 // INAD 4231	CVM	tox study	HHSafety
9/12/96 // INAD 4231	Elanco	Confirmatory Method Trial & Method	Tissue Method
9/17/96 // INAD 4231	Elanco	Determinative Method Trial & Method	Tissue Method
10/22/96 // I-004231	CVM	**Confirmatory Method is acceptable**	Tissue Method
12/13/96 // INAD 4231	Elanco	Tox data	HHSafety
12/16/96 // I-004231	CVM	**Determinative method is acceptable at 6 ppb and above.**	Tissue Method
12/17/96 // INAD 4231	Elanco	FOI and Labeling	Label
12/18/96 // INAD 4231	Elanco	Reactivate Efficacy Technical Section	Efficacy
1/22/97 // VMF 5477	Elanco	Stability data and proposed expiry dating	CM&C
6/2/97 // INAD 4231	Elanco	Technical Section complete letter	CM&C
6/20/97 // VMF 005-477	CVM	**VMF is complete, and 24 months expiration dating on Type A Article approved**	CM&C
7/30/97//INAD 004321	CVM	Tox data	HHSafety
8/11/97// INAD 4231	Elanco	Protocols for tox studies	HHSafety
8/12/97//INAD 4231	CVM	Technical section status	CM&C
1/16/98//INAD 004-231	CVM	Label claim	Label; Effic
2/25/98//INAD 4231	Elanco	Tox data	HHSafety
2/26/98//INAD 4231	Elanco	Label claim	Label; Effic
2/26/98//INAD 004-231	CVM	FOI and Labeling	Label; FOI
3/10/98//INAD 4231	Elanco	Tox data	HHSafety
6/2/98//INAD 004231	CVM	Tox data	HHSafety
7/9/98 // INAD	Elanco	Proposed swine muscle tolerance	Residue
9/9/98// INAD 4231	CVM	Safe concentration is set at 0.25 ppm in muscle and the **muscle tolerance is set at 50 ppb parent ractopamine.**	Tissue Method; Residue
10/27/98//INAD 4231	Elanco	Tox data	HHSafety
11/12/98//INAD 004-231	CVM	**Effectiveness Technical Section complete**	Label; Effic
11/19/98 // INAD 4231	Elanco	Tox data	HHSafety
12/11/98//INAD 4231	Elanco	C,M & C Technical Section status	CM&C
12/14/98//INAD 4231	Elanco	Validated muscle tissue methods	Tissue Method
12/17/98 // INAD 4231	Elanco	Updated FOI	FOI
2/17/99 // INAD 4231	Elanco	Updated FOI	FOI
2/18/99 // INAD 4231	Elanco	Labels	Label
3/26/99//INAD 004-231	CVM	**C,M & C technical section is complete.**	CM&C
04/08/99 // INAD 4231	Elanco	Camera-ready paper and electronic copy of EA	EA
5/24/99 // INAD 4231	CVM	**Human Health Safety Technical Section Complete.** Liver tolerance of parent compound is 0.150 ppm and for muscle is 0.05 ppm. **No withdrawal period is required in swine.**	HHSafety
6/17/99 // INAD 4231	CVM	Tox data	HHSafety
7/09/99 // INAD 4231	CVM	**Environmental Assessment technical section complete letter. FONSI attached.**	EA
9/27/99//INAD 4231	CVM	**Methods are acceptable for both Muscle and Liver tissues, therefore residue technical section is complete.**	Tissue Method
10/06/99 // INAD 004-231	CVM	**Freedom of Information technical section complete ; Labeling Technical Section Complete.**	Label; FOI
10/8/99 // NADA 140-863	Elanco	Administrative NADA	ALL
10/12/99 // NADA 140-863	Elanco	1st Amendment to Admin NADA – amended Type B&C labels	Label
11/3/99 // NADA 140-863	Elanco	2nd Amendment to Admin NADA – amended Type A&B labels	Label
12/12/99 // NADA 140-863	Elanco	3rd Amendment to Admin NADA – amended EA	EA; Patent

12/22/99 // NADA 140-863	CVM	and patent info Approval to market Paylean	ALL